CONITEC takes credit for Brazilian Herceptin court case fall
This article was originally published in Scrip
Executive Summary
A drop in the number of court cases brought by patients against Brazilian health authorities to access Roche's breast cancer drug Herceptin (trastuzumab) could be an early sign that the new health technology appraisal body, CONITEC, is doing a good job, it told Scrip.